Close Menu

BARDA

Overall, GenMark's ePlex Respiratory Pathogen Panel 2 provides results for more than 20 viruses and bacteria, including SARS-CoV-2, flu A and B, RSV, and rhinovirus.

Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.

The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.

 

The PCR diagnostic device is a palm-size, single-use, disposable device that detects N. gonorrhoeae and determines if it's susceptible to an antibiotic.

Rick Bright, the former BARDA director, updates his whistleblower complaint to include allegations of ongoing retaliation, CBS News reports.

The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.

The New York Times reports that a federal watchdog group has recommended Rick Bright be reinstated to his former post during its investigation of his whistleblower claims.

The Washington Post reports former BARDA Director Rick Bright alleges in a whistleblower complaint he was removed from his post for trying to "prioritize science and safety over political expediency."

The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.

Starting in late May, Hologic expects to begin producing at least 1 million Aptima SARS-CoV-2 assays per week, BARDA noted.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.